Moorthi, R. N. & Moe, S. M. Recent advances in the noninvasive diagnosis of renal osteodystrophy. Kidney Int 84, 886-894 (2013).
Torres, P. U., Bover, J., Mazzaferro, S., de Vernejoul, M. C. & Cohen-Solal, M. When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. Semin Nephrol 34, 612-625 (2014).
Vervloet, M. G. & Brandenburg, V. M. Circulating markers of bone turnover. J Nephrol. in press (2017).
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl S1-130 (2009).
Ketteler, M. et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int 92, 26-36 (2017).
Cavalier, E. et al. Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients. Clin Biochem 47, 1227-1230 (2014).
Souberbielle, J. C. et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 70, 345-350 (2006).
Delanaye, P., Souberbielle, J.-C., Lafage-Proust, M.-H., Jean, G. & Cavalier, E. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts. Nephrol Dial Transplant 29, 997-1004 (2014).
Cavalier, E., Delanaye, P., Collette, J., Krzesinski, J.-M. & Chapelle, J.-P. Evaluation of different bone markers in hemodialyzed patients. Clin Chim Acta 371, 107-111 (2006).
Reichel, H., Esser, A., Roth, H. J. & Schmidt-Gayk, H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial.Transplant 18, 759-768 (2003).
Delanaye, P. et al. Parathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: is it so simple? Clin Chim.Acta 417, 35-38 (2013).
Sprague, S. M. et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis 67, 559-566 (2016).
Torres, A. et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 47, 1434-1442 (1995).
Behets, G. J. et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87, 846-56 (2015).
Cavalier, E., Delanaye, P. & Moranne, O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis 61, 847-848 (2013).
Soohoo, M. et al. Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients. Am J Nephrol 43, 85-96 (2016).
Streja, E. et al. Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients. Bone 61, 201-207 (2014).
Mundy, G. R. & Guise, T. A. Hormonal control of calcium homeostasis. Clin Chem 45, 1347-1352 (1999).
Garrett, G., Sardiwal, S., Lamb, E. J. & Goldsmith, D. J. PTH-a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol 8, 299-312 (2013).
Sanchez, C. et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 19, 1587-1593 (2004).
Jean, G., Chazot, C. & Charra, B. 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol 68, 63-64 (2007).
Cavalier, E., Lukas, P., Carlisi, A., Gadisseur, R. & Delanaye, P. Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters. Clin Chim Acta 425, 117-118 (2013).
Reichel, H., Roth, H. J. & Schmidt-Gayk, H. Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients. Nephron Clin Pract 98, c112-c118 (2004).
Okabe, R. et al. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides. Clin Chem 47, 1410-1414 (2001).
Jean, G. et al. Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease. Clin Biochem 45, 436-439 (2012).
Vasikaran, S. et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22, 391-420 (2011).
Shidara, K. et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 82, 278-287 (2008).
Yamada, S. et al. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol 69, 189-196 (2008).
Malluche, H. H., Davenport, D. L., Cantor, T. & Monier-Faugere, M. C. Bone Mineral Density and Serum Biochemical Predictors of Bone Loss in Patients with CKD on Dialysis. Clin J Am Soc Nephrol 9, 1254-1262 (2014).